BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8691269)

  • 1. Bone marrow dosimetry: regional variability of marrow-localizing antibody.
    Sgouros G; Jureidini IM; Scott AM; Graham MC; Larson SM; Scheinberg DA
    J Nucl Med; 1996 Apr; 37(4):695-8. PubMed ID: 8691269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
    Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
    J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy.
    Ferrer L; Kraeber-Bodéré F; Bodet-Milin C; Rousseau C; Le Gouill S; Wegener WA; Goldenberg DM; Bardiès M
    Cancer; 2010 Feb; 116(4 Suppl):1093-100. PubMed ID: 20127958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.
    Siegel JA; Pawlyk DA; Lee RE; Sasso NL; Horowitz JA; Sharkey RM; Goldenberg DM
    Cancer Res; 1990 Feb; 50(3 Suppl):1039s-1042s. PubMed ID: 2297717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
    Shen S; Meredith RF; Duan J; Macey DJ; Khazaeli MB; Robert F; LoBuglio AF
    J Nucl Med; 2002 Sep; 43(9):1245-53. PubMed ID: 12215566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
    Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
    Acta Oncol; 2005; 44(6):579-88. PubMed ID: 16165917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
    Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
    Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
    Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
    J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
    J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of a breast-directed I-131-radiolabeled monoclonal antibody in blood and bone marrow: implications for radiation immunotherapy.
    Johnson TK; Gonzalez R; Kasliwal RK; Lear JL; Feyerabend AJ; Dienhart DG; Ceriani RL; Bunn PA
    Radiology; 1992 Jan; 182(1):107-14. PubMed ID: 1727271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.
    Sgouros G; Ballangrud AM; Jurcic JG; McDevitt MR; Humm JL; Erdi YE; Mehta BM; Finn RD; Larson SM; Scheinberg DA
    J Nucl Med; 1999 Nov; 40(11):1935-46. PubMed ID: 10565792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy.
    Macey DJ; DeNardo SJ; DeNardo GL; DeNardo DA; Shen S
    Clin Nucl Med; 1995 Feb; 20(2):117-25. PubMed ID: 7720301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy.
    Siegel JA; Lee RE; Pawlyk DA; Horowitz JA; Sharkey RM; Goldenberg DM
    Int J Rad Appl Instrum B; 1989; 16(6):553-9. PubMed ID: 2481657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody.
    Matthews DC; Badger CC; Fisher DR; Hui TE; Nourigat C; Appelbaum FR; Martin PJ; Bernstein ID
    Cancer Res; 1992 Mar; 52(5):1228-34. PubMed ID: 1531324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.
    Shen S; DeNardo GL; Sgouros G; O'Donnell RT; DeNardo SJ
    J Nucl Med; 1999 Dec; 40(12):2102-6. PubMed ID: 10616892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
    J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
    DeNardo GL; Kukis DL; Shen S; DeNardo DA; Meares CF; DeNardo SJ
    Clin Cancer Res; 1999 Mar; 5(3):533-41. PubMed ID: 10100704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.